<table>
<thead>
<tr>
<th>Name</th>
<th>Employment</th>
<th>Leadership</th>
<th>Stock and Other Ownership Interests</th>
<th>Honorsaria</th>
<th>Consulting or Advisory Role</th>
<th>Speakers' Bureau</th>
<th>Research Funding</th>
<th>Patents, Royalties, Other Intellectual Property</th>
<th>Expert Testimony</th>
<th>Travel, Accommodations, Expenses</th>
<th>Other Relationship</th>
<th>(OPTIONAL) Uncompensated Relationships</th>
<th>(OPTIONAL) Open Payments Link</th>
</tr>
</thead>
<tbody>
<tr>
<td>Charu Aggarwal</td>
<td>AstraZeneca</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>AstraZeneca (I)</td>
<td>Roche/Genentech (I)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>AstraZeneca/Immunocore (Inst)</td>
<td></td>
<td></td>
<td></td>
<td>Genentech/Roche (Inst)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Incyte (Inst)</td>
<td></td>
<td></td>
<td></td>
<td>Macrogenics (Inst)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Merck Sharp &amp; Dohme (Inst)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lauren A. Byers</td>
<td>Clinical Care Options</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Ablative</td>
<td>Amgen</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>AstraZeneca</td>
<td></td>
<td></td>
<td></td>
<td>Chugai Pharmaceuticals (Inst)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Daiichi Sankyo Genentech Co.</td>
<td></td>
<td></td>
<td></td>
<td>Jazz Pharmaceuticals (Inst)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Merck Sharp &amp; Dohme Corp.</td>
<td></td>
<td></td>
<td></td>
<td>Puma Biotechnology</td>
<td></td>
</tr>
<tr>
<td>Elizabeth A. Comen</td>
<td>Survivornet</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Bristol-Myers Squibb</td>
<td>Gilead Sciences</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Novartis (Inst)</td>
<td></td>
<td></td>
<td></td>
<td>Hoffman La Roche</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Novartis (Inst)</td>
<td></td>
<td></td>
<td></td>
<td>Pfizer</td>
<td></td>
</tr>
<tr>
<td>Curtland Deville</td>
<td>AstraZeneca</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>AstraZeneca Blue Earth Diagnostics</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Robert Dreicer</td>
<td>AstraZeneca</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Adelphi Pharma</td>
<td>AVEO</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>AstraZeneca</td>
<td></td>
<td></td>
<td></td>
<td>Bayer</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Gilead Sciences (Inst)</td>
<td></td>
<td></td>
<td></td>
<td>Genentech (Inst)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Novartis (Inst)</td>
<td></td>
<td></td>
<td></td>
<td>Novartis (Inst)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Janssen Oncology (Inst)</td>
<td></td>
<td></td>
<td></td>
<td>Merck</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Sanofi-Genzyme (Inst)</td>
<td></td>
<td></td>
<td></td>
<td>Sanofi-Genzyme (Inst)</td>
<td></td>
</tr>
</tbody>
</table>

2023 ASCO Cancer Communications Committee Disclosures
All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution

Charu Aggarwal

Lauren A. Byers

Elizabeth A. Comen

Curtland Deville

Robert Dreicer
<table>
<thead>
<tr>
<th>Name</th>
<th>Organization(s)</th>
</tr>
</thead>
</table>
| Cathy Eng             | Amgen (I)  
California Institute for Regenerative Medicine (CIRM) (I)  
Elevation Oncology  
General Electric  
GlaxoSmithKline  
Gritstone (Inst)  
IgM Biosciences (I)  
Janssen Oncology  
Merck (Inst)  
Pfizer (Inst) |
| Mark T. Fleming       | Virginia Oncology Associates  
US Oncology  
Dendreon  
Janssen Oncology  
Genentech  
Janssen Oncology (Inst)  
Merck (Inst)  
Pfizer (Inst) |
| Julie R. Gralow       | Virginia Oncology  
Astellas Pharma (Inst)  
Gritstone Bio (Inst)  
NCTchinson (Inst)  
Janssen Oncology (Inst)  
Merck (Inst)  
Pfizer (Inst) |
| Glenn J. Hanna        | Dana-Farber Cancer Institute  
Bristol-Myers Squibb  
Kutsche Oncology  
Bocasa  
Bocasa Capital  
Bristol-Myers Squibb  
Exicore  
General Catalyst  
KOC Therapeutics  
Kutsche Oncology  
Merck  
Naveris  
Poleic Therapeutics  
Ram Therapeutics  
Rams Therapeutics  
Sanofi Genzyme  
SIPPart  
Actuate Therapeutics (Inst)  
ASCO Conquer Cancer Foundation  
Bocasa Therapeutics (Inst)  
Bristol-Myers Squibb (Inst)  
Elevation Oncology  
Exicore (Inst)  
Gateways for Cancer Research  
GlaxoSmithKline (Inst)  
KOC Therapeutics (Inst)  
Kite/Gilead (Inst)  
Kite/Gilead (Inst)  
NantKwest (Inst)  
Regeneron (Inst)  
Sanofi Genzyme (Inst)  
Secura Bio (Inst)  
V Foundation  
Aerossom Rappaport  
Feinstein & Deutsch LLP  
Ahmuty, Demers, & McManus, Esq.  
Wilson Elser Moskowitz Edelman & Dicker, LLP |
| Melissa M. Hudson     | Oncology Research Information Exchange Network  
Princess-Maxima Cancer Center  
Bristol-Myers Squibb  
Kutsche Oncology  
Aveniris (Advanced Accelerator Applications) (Inst) |
| Pamela L. Kunz        | Amgen  
Gilead Sciences  
Santen (Inst)  
Novartis (Advanced Accelerator Applications) (Inst) |
| Michael C. Lowe       | Bristol-Myers Squibb  
Pfizer  
Bristol-Myers Squibb (Inst)  
Castle Biosciences (Inst)  
Deltath Systems (Inst)  
Regeneron (Inst)  
Sanofi Genzyme (Inst)  
Vaccine (Inst) |
<table>
<thead>
<tr>
<th>Ann H. Partridge</th>
<th>#I receive small royalty payments for co-authoring the breast cancer survivorship section of UpToDate</th>
</tr>
</thead>
<tbody>
<tr>
<td>#Methods and Genomic Classifiers for Prognosis of Breast Cancer and Predicting Benefit from Adjunct Radiotherapy. Application No. 61/205,279, Co-inventor, Submitted on</td>
<td></td>
</tr>
<tr>
<td>----------------</td>
<td>-----------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Jennifer F. Tseng</td>
<td>Aegerion (I) Amgen (I) Astellas (I) Bristol-Myers Squibb (I) Cedars (I) Curael Surgical Innovations Daiichi Sankyo/Lilly (I) GlaxoSmithKline (I) Intarcia Therapeutics (I) Merck (I) MyoKardia (I) ParTherapeutics Pfizer (I) Quest Diagnostics (I) Sanofi (I) Vertex (I) Zevia (I)</td>
</tr>
</tbody>
</table>